Shriya Gandhi, MD
1801 W TAYLOR ST STE 1C · Chicago, IL 60612
Telehealth
Listing updated Oct 2, 2026
Health & Slimness Through Semaglutide (LiteLift Clinic listing)
Health & Slimness Through Semaglutide — Chicago · 604 East 81st Street · Chicago, IL 60619
5.0· 76 Google reviews
Listing updated October 2, 2026
Retatrutide outlook for this practice
No current plans confirmed — RetaMaps has not yet confirmed this practice's intentions regarding retatrutide. Inclusion on RetaMaps does not mean the provider offers or will offer retatrutide.
About this practice
The official Chicago URL is a city-UTM LiteLift Clinic page (chicagosq.liteliftclinic.com) that looks like a multi-city SEO/lead-gen landing page rather than a verified brick-and-mortar office at 604 E 81st Street. The related liteliftclinic.com homepage markets non-surgical, physician-supervised weight-loss programs and names semaglutide therapy as Ozempic or Wegovy, plus HGH, TRT, and peptides; it uses a generic contact form, lists no local clinicians or phone, and even shows testimonials attributed to another clinic name. A physical Chicago practice was not independently confirmed on the live pages.
Services & access
| Advertises semaglutide today | Not listed |
| Advertises tirzepatide today | Not listed |
| Telehealth visits | — |
| Cash pay accepted | — |
| Accepts insurance — per practice website | — |
| Accepting new patients — per practice website | — |
"Not listed" means we didn't find this stated on the practice's public pages — it doesn't mean no. — means unknown. Medication rows describe currently FDA-approved GLP-1 medications the practice advertises today, not retatrutide. Confirm details directly with the practice.
Review activity
★ 5.0
Google rating · 76 reviews
16
reviews in the past year (avg ★ 4.9)
2
reviews mention weight loss
Counts computed by RetaMaps from public Google reviews; most recent review 2026-09-26. Read the reviews themselves on the practice's Google listing.
Nearby providers in Chicago
Semaglutide todayTirzepatide today
Listing updated Oct 2, 2026
Grant Barish, M.D.
676 N Saint Clair St Ste 701 · Chicago, IL 60611
TelehealthAccepts insurance
Listing updated Oct 2, 2026
Doctor's Orders Weight Loss Clinic
1300 W Belmont Suite 400 E · Chicago, IL 60657
5.0(49 Google reviews · 11 in past year)
TelehealthAccepts insuranceSemaglutide todayTirzepatide today6 reviews mention GLP-1
Listing updated Oct 2, 2026
Retatrutide status
Phase 3 complete · Not FDA-approvedUpdated October 2, 2026
Retatrutide is Eli Lilly's investigational once-weekly triple agonist (GIP, GLP-1 and glucagon receptors). Five Phase 3 trials have reported positive results, and Lilly plans to submit it to the FDA in Q1 2027. It is not FDA-approved, has no brand name or price, and cannot be prescribed outside clinical trials or Lilly's physician-requested expanded access program. Products sold online as "research" or compounded retatrutide are not legitimate retatrutide.
- Development
- Phase 3 complete
- FDA status
- Submission planned — Q1 2027 (Lilly guidance)
- Availability
- Not commercially available
- Access routes
- Clinical trials, or Lilly's expanded access program (physician must apply)
Next milestone: TRIUMPH-5 head-to-head vs tirzepatide results (Expected ~Dec 2026)
Sources: Lilly — What to know about retatrutide · Lilly — TRIUMPH-2/TRIUMPH-3 results · BioPharma Dive — FDA submission plans · STAT — Lilly expanded access (Aug 3, 2026) · FDA — Concerns with unapproved GLP-1 drugs